Meeting abstract

Allergy, Asthma & Clinical Immunology

, 8:A19

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients

  • Adriana MartinAffiliated withSCIG Home Infusion Program, St. Paul’s Hospital Email author 
  • , Robert SchellenbergAffiliated withSCIG Home Infusion Program, St. Paul’s Hospital